Advertisement
Research Article

Efficacy and Safety of Three Antiretroviral Regimens for Initial Treatment of HIV-1: A Randomized Clinical Trial in Diverse Multinational Settings

  • Thomas B. Campbell mail,

    thomas.campbell@ucdenver.edu

    Affiliation: Division of Infectious Diseases, Department of Medicine, University of Colorado School of Medicine, Aurora, United States of America

    X
  • Laura M. Smeaton,

    Affiliation: Center for Biostatistics in AIDS Research, Harvard School of Public Health, Boston, Massachusetts, United States of America

    X
  • N. Kumarasamy,

    Affiliation: YRG Centre for AIDS Research & Education, Chennai, India

    X
  • Timothy Flanigan,

    Affiliation: Brown Medical School, Providence, Rhode Island, United States of America

    X
  • Karin L. Klingman,

    Affiliation: National Institutes of Health, Bethesda, Maryland, United States of America

    X
  • Cynthia Firnhaber,

    Affiliation: Clinical HIV Research Unit, Department of Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa

    X
  • Beatriz Grinsztejn,

    Affiliation: Evandro Chagas Clinical Research Institute, Fiocruz, Rio de Janeiro, Brazil

    X
  • Mina C. Hosseinipour,

    Affiliation: Kamuzu Central Hospital, Lilongwe, Malawi

    X
  • Johnstone Kumwenda,

    Affiliation: Department of Medicine, College of Medicine, Blantyre, Malawi

    X
  • Umesh Lalloo,

    Affiliation: Nelson R. Mandela School of Medicine, Durban, South Africa

    X
  • Cynthia Riviere,

    Affiliation: Institut Nacional de laboratoire et de Recherches, Port-au-Prince, Haiti

    X
  • Jorge Sanchez,

    Affiliation: Asociación Civil Impacta Salud y Educación, Lima, Peru

    X
  • Marineide Melo,

    Affiliation: Servico de Infectology, Hospital Nossa Senhora da Conceicao-GHC, Porto Alegre, Brazil

    X
  • Khuanchai Supparatpinyo,

    Affiliation: Department of Medicine and Research Institute for Health Sciences, Chiang Mai University, Chiang Mai, Thailand

    X
  • Srikanth Tripathy,

    Affiliation: National AIDS Research Institute, Pune, India

    X
  • Ana I. Martinez,

    Affiliation: National Institutes of Health, Bethesda, Maryland, United States of America

    X
  • Apsara Nair,

    Affiliation: Frontier Science & Technology Research Foundation, Amherst, Massachusetts, United States of America

    X
  • Ann Walawander,

    Affiliation: Frontier Science & Technology Research Foundation, Amherst, Massachusetts, United States of America

    X
  • Laura Moran,

    Affiliation: Social & Scientific Systems, Inc, Silver Spring, Maryland, United States of America

    X
  • Yun Chen,

    Affiliation: Center for Biostatistics in AIDS Research, Harvard School of Public Health, Boston, Massachusetts, United States of America

    X
  • Wendy Snowden,

    Affiliation: GlaxoSmithKline, Research Triangle Park, North Carolina, United States of America

    X
  • James F. Rooney,

    Affiliation: Gilead Sciences, Inc., Foster City, California, United States of America

    X
  • Jonathan Uy,

    Affiliation: Bristol-Myers Squibb Company, Plainsboro, New Jersey, United States of America

    X
  • Robert T. Schooley,

    Affiliation: University of California San Diego, San Diego, United States of America

    X
  • Victor De Gruttola,

    Affiliation: Center for Biostatistics in AIDS Research, Harvard School of Public Health, Boston, Massachusetts, United States of America

    X
  • James Gita Hakim, for the PEARLS study team of the ACTG,

    Affiliation: University of Zimbabwe College of Health Sciences, Harare, Zimbabwe

    X
  • Edith Swann

    Membership of the AIDS Clinical Trials Group PEARLS Team is provided in the Acknowledgments.

    X
  • Published: August 14, 2012
  • DOI: 10.1371/journal.pmed.1001290

Media Coverage of this Article

Found additional news media or blog coverage for the article? Please let us know.

Linked Articles

What Is the Optimal First Line Antiretroviral Therapy in Resource-Limited Settings?

Chris Kenyon, Robert Colebunders
Perspective | published 14 Aug 2012 | PLOS Medicine
doi:10.1371/journal.pmed.1001291